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Abstract
Stem cell-based gene therapies, wherein stem cells are genetically engineered to express 
therapeutic molecules, have shown tremendous potential for cancer applications owing to their 
innate ability to home to tumors. However, traditional stem cell-based gene therapies are 
hampered by our current inability to control when the therapeutic genes are actually turned on, 
thereby resulting in detrimental side effects. Here, we report the novel application of magnetic 
core-shell nanoparticles for the dual purpose of delivering and activating a heat-inducible gene 
vector that encodes TNF-related apoptosis-inducing ligand (TRAIL) in adipose-derived 
mesenchymal stem cells (AD-MSCs). By combining the tumor tropism of the AD-MSCs with the 
spatiotemporal MCNP-based delivery and activation of TRAIL expression, this platform provides 
an attractive means with which to enhance our control over the activation of stem cell-based gene 
therapies. In particular, we found that these engineered AD-MSCs retained their innate ability to 
proliferate, differentiate, and, most importantly, home to tumors, making them ideal cellular 
carriers. Moreover, exposure of the engineered AD-MSCS to mild magnetic hyperthermia resulted 
in the selective expression of TRAIL from the engineered AD-MSCs and, as a result, induced 
significant ovarian cancer cell death in vitro and in vivo.
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Ovarian cancer currently ranks fifth in cancer mortalities among women and is the leading 
cause of death from gynecological malignancies [1]. The conventional mode of therapy for 
this cancer consists of cytoreductive surgery, followed by adjuvant platinum/taxane-based 
chemotherapy [2]. However, while most ovarian cancer patients exhibit initial sensitivity to 
chemotherapy, over 70% of these patients are diagnosed at an advanced stage, when the 
tumors have already metastasized throughout the peritoneal cavity [3]. As a consequence, 
the majority of ovarian cancer patients experience recurrence within 18–24 months of 
treatment and only 20% of them survive longer than 5 years after their initial diagnosis [4].
To enhance the treatment of advanced cancers, such as advanced ovarian cancer, 
mesenchymal stem cell (MSC)-based therapies have emerged as an attractive alternative that 
can overcome the limited tumor-targeting ability of conventional treatments [5]. MSCs have 
the intrinsic ability to self-renew and differentiate into multiple lineages including 
osteoblasts, chondrocytes, and adipocytes [6]. More importantly, several groups have 
demonstrated that these stem cells have the innate ability to migrate to tumors including 
ovarian tumors/metastases, even following systemic administration [7–10]. While the exact 
mechanism is still being elucidated, this tumor tropism has prompted the development of 
stem cell-based gene therapies, wherein MSCs are genetically engineered to express 
therapeutic molecules and therefore, act as targeted delivery vehicles to enhance our ability 
to treat metastatic cancers [11, 12].
To this end, a number of therapeutic molecules have been investigated, including direct 
effectors of apoptosis, such as the cytokines, interferon-β (IFN-β)[13] and tumor necrosis 
factor-related apoptosis inducing ligand (TRAIL) [14], as well as more indirect 
immunomodulatory molecules like interleukin 12 (IL-12) [15]. Of these, TRAIL is a 
particularly attractive therapeutic candidate owing to its ability to selectively induce 
apoptosis in malignant cells, but not in most normal cells [16]. For example, Mueller et al. 
reported that multipotent MSCs that were genetically engineered to express TRAIL were 
able to induce apoptosis and inhibit the growth of colorectal carcinoma cells in vivo with no 
serious observable side effects [17]. Similarly, Loebinger and colleagues demonstrated that 
MSCs engineered to produce and deliver TRAIL could induce apoptosis in lung, breast, 
squamous, and cervical cancer cells [14]. Importantly, these engineered MSCs were able to 
significantly reduce tumor growth in a subcutaneous breast cancer xenograft and could 
home to and reduce lung metastasis. However, while TRAIL has largely been demonstrated 
to be biocompatible with normal cells, there have been a number of reports indicating 
potential hepatotoxicity upon treatment with TRAIL, thereby greatly dampening its clinical 
potential [18, 19]. As such, to limit these potentially detrimental side effects and in order for 
stem cell therapies to reach their full potential, there remains a pressing need for approaches 
that can allow for the precise spatiotemporal control of therapeutic gene activation such that 
the engineered stem cells only express their therapeutic payload once they have reached the 
targeted tumor sites.
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Herein, we report the novel application of magnetic core-shell nanoparticles (MCNPs), 
composed of a highly magnetic zinc-doped iron oxide (ZnFe2O4) core and a biocompatible 
mesoporous silica (mSi) shell, for the dual purpose of delivering and activating a heat-
inducible gene vector that encodes a secretable form of TRAIL in MSCs (Figure 1). For this 
purpose, we developed a plasmid with the heat shock protein 70B’ (HSP70B’) promoter 
(Figure 1B), which has previously been demonstrated to be more heat-specific than other 
heat shock promoters [20]. As such, the MSCs can first be engineered with MCNPs that are 
complexed with the heat-inducible TRAIL plasmid in vitro. Afterwards, following in vivo 
injection and migration of the engineered MSCs to the targeted tumor sites, TRAIL 
expression can be specifically activated via the induction of mild magnetic hyperthermia 
(~41°C). In this report, we demonstrated the efficient and biocompatible uptake of MCNP-
plasmid complexes into MSCs. In particular, we observed that the engineering process had 
no significant effects on MSC proliferation or differentiation. Moreover, the engineered 
MSCs retained their tumor tropism towards disseminated peritoneal ovarian cancer 
xenografts. Importantly, we demonstrated that mild magnetic hyperthermia, via exposure of 
the engineered MSCs to an alternating magnetic field (AMF), could be used to specifically 
raise the intracellular temperature to ~41°C, which resulted in the selective expression of 
TRAIL in the engineered MSCs. As a result, significant ovarian cancer cell apoptosis and 
death was observed in vitro and in vivo. Overall, by combining the tumor tropism of MSCs 
with the spatiotemporal MCNP-based delivery and activation of TRAIL expression, this 
platform provides an attractive means with which to enhance our control over the activation 
of stem cell-based gene therapies.
2. MATERIALS AND METHODS
2.1. Nanoparticle Synthesis and Characterization
The synthesis of ZnFe2O4 magnetic nanoparticles (MNPs) has previously been reported and 
modified by our group [21–25]. Briefly, 1.35 mmol, 0.3 mmol, and 0.7 mmol of Fe(acac)3, 
ZnCl2, and FeCl2, respectively, were mixed into a round bottom flask with 20 mL of tri-n-
octylamine, 6 mmol of both oleic acid and oleylamine, and 10 mmol of 1,2 hexadecanediol. 
The reaction mixture was then heated up to 200°C for 2 hrs. From here, the mixture was 
heated to 305°C for 2 hrs and the nanoparticles were purified by repeatedly washing with 
ethanol.
To coat the MNP cores with a mSi shell, a modified procedure from what was reported by 
Hyeon et al. was used [26]. 5 mg of the alkyl-capped MNP cores dispersed in chloroform 
were sonicated using a probe type sonicator in a 0.1 M aqueous cetyltrimethylammonium 
bromide (CTAB) solution. Upon evaporation of chloroform, the CTAB capped MNP cores 
were diluted to 50 mL with water and the pH of this mixture was adjusted to ~ 11 using a 
2M NaOH solution. This reaction mixture was heated to 70°C and, under vigorous stirring, 
0.4 mL of tetraethylorthosilicate (TEOS) in 2.4 mL of ethyl acetate was added. After the 
addition of TEOS, the reaction was allowed to continue for 4 hrs. The MCNPs were 
collected and washed several times with ethanol. To remove the template, the nanoparticles 
were heated to 60°C in an ammonium nitrate solution. The extracted MCNPs were again 
washed with ethanol. Finally, the MCNPs were characterized by high-resolution 
Yin et al. Page 3













Transmission electron microscopy (HR-TEM) and Fourier-transform infrared spectra 
(FTIR).
To characterize the magnetic properties of the nanoparticles, the resulting MCNPs (25 
µg/mL in H2O) were exposed to an AMF (5 kA/m, 225 kHz) using a solid-state induction 
heating system (Superior Induction Company) for one hour. The temperature of the solution 
was monitored using a fiber optic temperature probe (LumaSense Technologies). To 
calculate the specific absorption rate (SAR), the following equation was used:
where C is the specific heat capacity, ms is the mass of the solution, mm is the mass of the 
magnetic nanoparticles, T is the temperature, and t is the time [27].
2.2. Construction of the plasmids
To construct the plasmids, we first cloned the recombinant gene that encodes a secreted 
form of the human TRAIL protein into the pEGFNP-N1 backbone (Clonetech) thereby 
creating a secretable TRAIL-EGFP fusion that is constitutively active (e.g. via CMV 
promoter) to allow for monitoring (sTRAIL-EGFP plasmid). In particular, the secreted form 
of TRAIL was kindly provided by Drs. Leaf Huang (Department of Biomedical 
Engineering, University of North Carolina at Chapel Hill) and Yukai He (Cancer Center, 
Georgia Health Sciences University) [28]. This recombinant TRAIL gene (sTRAIL) was 
composed of the soluble form of the human Flt3L gene (hFlex) at the 5’ end and the human 
TRAIL gene at the 3’ end (aa residues 95–281) with an isoleucine zipper at the N-terminal 
of TRAIL, which was previously shown to significantly enhance trimerization of the fusion 
protein as well as its anti-tumor activity [28]. As such, the cDNA for sTRAIL was amplified 
using PCR by employing the 5’ and 3’ primers 5’-
CGGCCGCTCGAGATGACAGTGCTGGCGCCA-3’ and 5’-
CGCCGCAAGCTTTTAGCCAACTAAAAAGGC-3’, respectively. In this way, the 5’ end 
of the PCR product contained the XhoI restriction site and the 3’ end of the PCR product 
contained the HindIII site. This 1 kb PCR product was digested with XhoI/HindIII and then 
cloned into pEGFNP-N1 to create the sTRAIL-EGFP fusion. The plasmid was denoted 
sTRAIL-EGFP. Similarly, HSP70B’ was ordered from Addgene (Plasmid #19486) [29]. The 
cDNA for the HSP70B’ promoter was amplified using PCR by employing the 5’ and 3’ 
primers 5’-GACAATTAATACCATGCAGGCCCCACGGGAGCT-3’ and 5’-
CGGCGCTCGAGTCAATCAACCTCCTCAATGA-3’, respectively. In this way, the 5’ end 
of the PCR product contained the AseI restriction site and the 3’ end of the PCR product 
contained the XhoI site. This 200 bp PCR product was digested with AseI/XhoI and then 
cloned into the sTRAIL-EGFP plasmid thereby creating the final HSP-sTRAIL plasmid. 
The open reading frames of the fusion proteins were confirmed by DNA sequencing 
(Macrogen).
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2.3. Formation of MCNP-PEI/plasmid complexes
To prepare the aforementioned MCNPs for plasmid delivery, the negatively charged 
MCNPs were coated with a branched cationic polymer, polyethyleneimine (PEI), which 
affords the MNPs with an overall positive charge. PEI is a polymer that is partially 
protonated under physiological conditions, thus allowing for the formation of complexes in 
the presence of nucleic acids [30]. PEIs have been used extensively for the delivery of 
plasmids and nucleic acids including small interfering RNAs (siRNAs) and microRNAs 
[30–32]. Specifically, it has been demonstrated that PEI-based complexes are able to enter 
the cell via caveolae- or clathrin-dependent routes and are able to facilitate release from the 
endosome with high efficiency via the “proton sponge effect [33].”
To obtain PEI-coated MCNPs, the MCNPs, dispersed in a minimal amount of ethanol, were 
added to a stirring solution containing excess PEI (MW=25,000; Mn=10,000) and 20 mM 
NaCl. This PEI molecular weight (MW) and structure was chosen based on previous reports 
[34]. After spinning overnight, the PEI-coated MCNPs were filtered using a centrifugal filter 
unit (EMD Millipore, 10,000 MW) to remove excess PEI. To complex the PEI coated 
MCNPs with plasmid, MCNP-PEI were diluted in a 20 mM NaCl solution and plasmid was 
added to the solution. Complexing was allowed to occur for 20 minutes.
To determine the initial concentration of MNP-PEI that needed to be added to complex 200 
ng/mL of plasmid, complexes with increasing concentrations of MNP-PEI were incubated 
with 200 ng/mL of plasmid. Afterwards, 100 µL of solution were transferred to a 96-well 
(black-walled, clear-bottom, non-adsorbing) plate (Corning, NY, USA). A total of 100 µL of 
diluted PicoGreen dye (1:200 dilution in Tris-EDTA (TE) buffer) was added to each sample. 
Fluorescence measurements were made after 10 minutes of incubation at room temperature 
using a M200 Pro Multimode Detector (Tecan USA Inc, NC, USA), at an excitation and 
emission wavelength of 480 and 520 nm, respectively. All measurements were corrected for 
background fluorescence from a solution containing only buffer and PicoGreen dye.
To characterize the MCNP-PEI/plasmid complexes, dynamic light scattering (DLS) and 
Zeta Potential analyses were performed using a Malvern Instruments Zetasizer Nano ZS-90 
instrument (Southboro, MA) with reproducibility being verified by the collection and 
comparison of sequentially obtained measurements. MCNP-PEI/plasmid complexes, were 
prepared using purified water (resistivity = 18.5 MΩ-cm). DLS measurements were 
performed at a 90° scattering angle at 25°C. Z-average sizes of three sequential 
measurements were collected and analyzed. Zeta potential measurements were collected at 
25°C, and the Z-average potentials following three sequential measurements were collected 
and analyzed.
2.4. Transfecting Cells with MCNP-PEI/plasmid complexes
Twenty-four hours before the magnetofection of MCNP complexes, A2780 ovarian cancer 
(ATCC) or human adipose-derived mesenchymal stem cells (AD-MSCs from Lonza 
[catalog # PT-5006]) were seeded into each well of a 12-well plate, so as to attain 80% 
confluency at the time of transfection. MNPPEI/ plasmid complexes were formed as 
described above. Thereafter, the MCNP complexes were mixed with Opti MEM (Life 
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Technologies) and added to each well to attain the desired final concentration of plasmid/
well. Subsequently, the cell culture plates were placed on a static Nd-Fe-B magnetic plate 
(OZ Biosciences, France) for 10 minutes (as optimized from previous reports) [23]. The 
culture plates were placed back into the incubator for 5 hrs and afterwards, the cells were 
washed with DPBS and the transfection medium was replaced with fresh growth medium. 
The growth mediums for the cell lines (obtained from ATCC or Lonza) used in the study are 
as follows: A2780 (DMEM supplemented with 10% FBS, 1% Penicillin-Streptomycin, and 
1% Glutamax) and AD-MSCs (Lonza ADSC Basal Medium [Catalog # PT-3273] with 
ADSC-GM SQ kit [Catalog # PT-4503]).
2.5. Magnetic Hyperthermia
Twenty-four hours after transfection, cells were washed with DPBS, trypsinized, and 
exposed to an AMF (5 kA/m, 225 kHz) for the desired amount of time. In particular, to 
achieve a constant temperature of ~41°C, the cells were initially exposed to an AMF for 20 
minutes to achieve a temperature of ~43 °C. Afterwards, the cells were periodically exposed 
to the AMF (5 minutes on, 5 minutes off) to maintain the temperature at ~41°C. Thereafter, 
fresh media was added to the treated cells and the cells were plated back into 12-well plates.
2.6. Cell Viability Assays
The percentage of viable cells was determined by MTT assay following standard protocols 
as described by the manufacturer. All measurements were made 48 hrs after initial 
transfection. All experiments were conducted in triplicate and averaged. The data is 
represented as formazan absorbance at 490 nm, considering the control (untreated) cells as 
100% viable.
2.7. Mild Magnetic Hyperthermia-Activated TRAIL Expression from AD-MSCs to Induce 
Apoptosis in Ovarian Cancer Cells
24 hours after the transfection of AD-MSCs with MCNP-PEI/plasmid complexes (50 µg/mL 
MCNP, 200 ng/mL of plasmid), we exposed the cells to an AMF (same conditions as 
described previously) to maintain a temperature of approximately 41°C for one hour. About 
72 hours after initial transfection, we collected the conditioned media from the engineered 
AD-MSCs, which contains TRAIL that was secreted from the engineered AD-MSCs, and 
added it (60:40 ratio with normal A2780 growth media) to the A2780 ovarian cancer cells. 
Following an additional incubation of 48 hours, its therapeutic efficacy was evaluated using 
MTT assay.
2.8. Cell Differentiation
To confirm the osteogenic potential of the MSCs used, AD-MSCs were incubated in CEM 
until a confluent layer was achieved and then osteogenic medium was added, containing 
IMDM supplemented with 9 % FBS, 9 % HS, 2 mM L-glutamine, 100 U/mL penicillin, 100 
µg/mL streptomycin, 50 ng/mL L-thyroxine (Sigma Aldrich), 20 mM β-glycerol phosphate, 
(Sigma Aldrich), 100 nM dexamethansone (Sigma Aldrich) and 50 µM ascorbic acid (Sigma 
Aldrich). Medium was changed every 3–4 days. After 21 days, cells were fixed in 10 % 
formalin, rinsed with DPBS and Alizarin Red S assay was used to assess mature bone 
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differentiation. In particular, DPBS was removed and the Alizarin Red solution (40mM, pH 
4.2) was added to each well and kept for 30 min with gentle shaking. The pH of the Alizarin 
Red solution was carefully adjusted using a pH meter (Accumet Basic, AB15, Fisher 
Scientific, USA). The solution was then removed and cells were washed with DI water five 
times. Following, the calcium-stained cells were imaged using an optical microscope 
(Eclipse Ti-U, Nikon, Japan). To quantitative these results, cells were destained using 10% 
cetylpyridinium chloride (CPC) in 10 mM sodiumphosphate (pH 7.0) for 30 minutes at 
room temperature. Finally, the concentration Alizarin Red S was determined by measuring 
its absorbance at 562 nm on a multiplate reader (Tecan, Switzerland).
2.9. Immunocytochemistry
Cell cultures were fixed with 4% formaldehyde (ThermoScientific) for 15 min, blocked for 
1 hr with 5% normal goat serum (NGS, Life Technologies), and permeabilized with 0.3% 
Triton X-100 when staining for intracellular markers (Ki-67). The primary antibody for 
Ki-67 (1:400, Cell Signaling, catalog # 9449S) was incubated overnight at 4°C. Alexa Fluor 
546-conjugated secondary antibodies were used to detect the primary antibodies (1:200, 
Molecular Probes) and Hoechst 33342 (1:100, Life Technologies) was used as a nuclear 
counterstain. The substrates were mounted on glass slides using ProLong® Gold antifade 
(Life Technologies) and imaged using a Nikon TE2000 Fluorescence Microscope.
2.10. PCR Analysis
Total RNA was extracted 48 hrs after initial transfection using Trizol Reagent (Life 
Technologies) and the mRNA expression level of genes of interest (Table S1) were analyzed 
using quantitative PCR (qPCR). Specifically, cDNA was generated from 1 µg of total RNA 
using the Superscript III First-Strand Synthesis System (Life Technologies). Analysis of the 
mRNA was then accomplished using primers specific to each of the target mRNAs. qPCR 
reactions were performed using SYBR Green PCR Master Mix (Applied Biosystems) on a 
StepOnePlus Real-Time PCR System (Applied Biosystems) and the resulting Ct values were 
normalized to GAPDH. Standard cycling conditions were used for all reactions with a 
melting temperature of 60°C. Primers are listed in Table S1.
2.11. Mechanistic Studies
For the blocking experiments, A2780 ovarian cancer cells were incubated in growth medium 
containing 10 ug/mL of the respective blocking antibodies for 1 hour before the addition of 
conditioned media from the engineered AD-MSCs (60:40 ratio with normal A2780 growth 
media). In particular, mouse monoclonal TRAIL-R1/DR4 (Enzo Life Sciences) and mouse 
monoclonal TRAIL-R2/DR5 (Enzo Life Sciences) antibodies were used for these 
experiments. Cell viability was then evaluated 24 hrs after the addition of conditioned media 
using MTT assay.
To inhibit caspases, the pan-caspase inhibitor, Z-VAD-FMK (Enzo Life Sciences), and the 
caspase-8 inhibitor, Z-IETD-FMK (Enzo Life Sciences), were used. For Z-VAD-FMK, a 10 
mM stock solution of the inhibitor was prepared using DMSO and the final concentration of 
the inhibitor and DMSO that the A2780 ovarian cancer cells were exposed to was 20 µM 
and 0.1%, respectively. For Z-IETD-FMK, a 10 mM stock solution of the inhibitor was 
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prepared using DMSO and the final concentration of the inhibitor and DMSO that the 
A2780 ovarian cancer cells were exposed to was 2 µM and 0.1%, respectively. The A2780 
ovarian cancer cells were treated with the inhibitors at the same time as the addition of the 
conditioned media (60:40 ratio with normal A2780 growth media). Cell viability was then 
evaluated 24 hrs after the addition of conditioned media and inhibitors using MTT assay.
For TRAIL immunoprecipitation, MCNPS were conjugated with TRAIL monoclonal 
antibodies (Santa Cruz Biotechnology). For this purpose, the MCNPs were first 
functionalized with primary amines via the grafting of aminopropyltriethoxysilane 
(APTES). This was performed by refluxing up to 50 mg of MCNPs in 40 mL of toluene 
with 20 uL of APTES overnight under dry conditions. The resulting aminefunctionalized 
MCNPs were then washed several times with ethanol and resupended in DMF. The TRAIL 
antibody (30 uL of 0.1 mg/mL solution) was activated with EDC/NHS coupling in 250 uL 
of DMF. Then, 1 mg of MCNPs dispersed in 250 uL of DMF was added to the activated 
TRAIL antibody and allowed to stir overnight. The resulting particles were washed several 
times with water and finally resuspended in DPBS. To perform MCNP-based 
immunoprecipitations, 200 µl of the antibody-conjugated MCNPs (1 mg/mL) was added to 
500 µl of conditioned media and incubated on ice for 30 min. To separate the nanoparticles 
from the conditioned media, a magnet was placed on the side of the tube for 5 minutes and 
the supernatant was carefully collected and transferred to a new tube. The supernatant was 
then added to A2780 cells (60:40 ratio with normal A2780 growth media) and cell viability 
was evaluated 24 hrs later using MTT assay.
2.12. Animal Studies
Human ovarian cancer cells (A2780) expressing the luciferase enzyme were purchased from 
Cell Biolabs, Inc (San Diego, CA). Cells were cultured in DMEM media with L-glutamine 
(Lonza, Walkersvile, MD) supplemented with 10% fetal bovine serum (Invitrogen, 
Carlsbad, CA), and 1.2 mL/100 mL penicillin-streptomycin (Gibco, Grand Island, NY). All 
cells were grown in a humidified atmosphere of 5% CO2 (v/v) at 37°C. All experiments 
were performed on the cells in the exponential growth phase.
6–8 weeks old Athymic nu/nu mice (NCRNU-M, CrTac: NCr-Foxn1nu) were obtained from 
Taconic (Hudson, NY, USA). All mice were maintained in micro-isolated cages under 
pathogen free conditions in the animal maintenance facilities of Rutgers, The State 
University of New Jersey. The research involving animals has been reviewed and approved 
by the Institutional Animal Care and Use Committee before any research was conducted. 
Orthotopic (intraperitoneal) ovarian cancer model was created by intraperitoneally injecting 
2 × 106 ovarian cancer cells (A2780) labeled with luciferase into the mice. Luciferase 
transfected cancer cells were visualized in live anesthetized animals using an in vivo 
bioluminescence IVIS system (Xenogen, Alameda, CA). Luciferin (150 mg/kg) was 
intraperitoneally administered 10 min before imaging. Mice were anesthetized with 
isoflurane (4% for induction of anesthesia and 1–2% for maintenance) using a XGI-8 Gas 
Anesthesia System (Xenogen, Alameda, CA) for imaging as previously described [35, 36].
After allowing up to 2 weeks for the tumors to develop, AD-MSCs were administered. For 
AD-MSC injection, AD-MSCs were engineered with MCNP-PEI/plasmid complexes as 
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described above. 24 hours after transfection, Vybrant DiD Cell-labeling solution was used 
(Molecular Probes, Catalog # V-22887) to label the cells prior to administration to animals. 
Specifically, staining media was prepared by adding 5 µL of the supplied DiD solution for 
every 1 mL of normal growth media required. The media from the engineered or 
unengineered AD-MSCs were then removed and replaced with staining media. AD-MSCs 
were incubated with staining media for 30 minutes. Afterwards, the labeled AD-MSCs were 
washed three times with DPBS, trypsinized, and then resuspended such that there were 5 × 
105 cells per 300 µL DPBS. As such, each animal received an intraperitoneal injection of 5 × 
105 cells in 300 µL of DPBS. As a control, a single dose of 200 µL (5 mg/kg) of 
recombinant TRAIL (ProSpec) in DPBS was injected intraperitoneally on day 0. Tumor 
volume of all animals was then monitored over two weeks by monitoring tumor 
luminescence. Please note that each group in each experiment had at least three mice.
3. RESULTS AND DISCUSSION
3.1. Synthesis and Characterization of the Magnetic Core-Shell Nanoparticles
For the dual purpose of delivering a heat-inducible therapeutic plasmid to the stem cells as 
well as spatiotemporally activating the plasmid via mild magnetic hyperthermia, we 
synthesized MCNPs with a zinc-doped iron oxide (ZnFe2O4) core. These cores have 
previously been shown to have a significantly higher saturation magnetization when 
compared to conventional Fe2O3 or Fe3O4 magnetic nanoparticles (MNPs) [25]. As such, 
we first synthesized ZnFe2O4 cores with a doping percentage of (Zn0.4Fe0.6)Fe2O4 via the 
thermal decomposition of a mixture of metal precursors (zinc chloride, ferrous chloride, and 
ferric acetylacetonate) in the presence of oleic acid and oleylamine using a previously 
reported protocol that was modified by our group [23, 25]. Following core synthesis, an inert 
mSi shell was formed via the condensation of TEOS in the presence of a CTAB micelle 
template [26]. TEM revealed that the diameter of the cores was 18.93 ± 1.6 nm and that the 
MNP cores were uniformly coated with a 33.91 ± 3.8 nm thick mSi shell. As a result, the 
overall diameter of the as-synthesized MCNPs was 88.03 ± 8.22 nm (Figure 2A). For more 
detailed characterization, HR-TEM revealed the monocrystalline structure of the MNP cores 
with a lattice fringe that was measured to be 4.8 Å (Figure S1A), which is characteristic of 
the (111) plane of the spinel [23, 25]. Finally, FTIR analysis was used to confirm that the 
CTAB template had been extracted and removed from the pores of the mSi shell (Figure 
S1B). In addition, the pores were estimated to be approximately 3 nm in diameter based on 
HR-TEM (Figure 2B) as well as previous reports [26].
To prepare the aforementioned MCNPs for plasmid delivery, the MCNPs were coated with 
branched polyethylenimine (PEI, MW = 10 kDa) via electrostatic interactions in the 
presence of NaCl to afford the MCNPs with an overall positive charge. As a result, this 
would facilitate MCNP complexation with negatively-charged plasmid DNA and induce 
endosomolysis within the cytoplasm [37]. To minimize cytotoxicity while maximizing 
transfection efficiency, we used 10 kDa branched PEI, which has previously been 
demonstrated to be biocompatible with stem cells [21, 38]. The resulting water soluble PEI-
coated MCNPs (MCNP-PEI) had a hydrodynamic size of 117.2 ± 37 nm (polydispersity 
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index [PDI] = 0.177) as measured by dynamic light scattering (DLS) and a zeta potential of 
+44.23 ± 0.72 mV (Figures 2C and S2A).
Finally, the MCNPs were characterized by a specific absorption rate (SAR) of 564 W/g, 
which was determined using an AMF with an amplitude of 5 kA/m and a frequency of 225 
kHz. This SAR is consistent with data reported in the literature for similar ZnFe2O4 MNPs 
[21, 39]. Moreover, we demonstrated that these MCNPs (25 µg/mL) could reach 
temperatures as high as 47°C within an hour of exposure to the AMF (Figure 2D) and that 
we could maintain a mild hyperthermia temperature of 41–43°C following periodic exposure 
to the AMF (5 minutes on, 5 minutes off, Figure S2B). As such, we were able to synthesize 
monodisperse water-soluble MCNPs with a narrow size distribution and, more importantly, 
these MCNPs had excellent magnetic properties for magnetic hyperthermia even after the 
addition of an mSi shell.
3.2. Heat-Inducible Plasmid Construction
Next, in order to attain control over the secretion of TRAIL from the engineered stem cells 
using mild magnetic hyperthermia, we constructed a heat-inducible TRAIL plasmid using 
the HSP70B’ promoter (HSP-sTRAIL plasmid, Figure 3A). To this end, we first cloned the 
recombinant gene that encodes a secreted form of the human TRAIL protein into the 
pEGFNP-N1 backbone (Clonetech), thereby creating a secretable TRAIL-EGFP fusion that 
was constitutively active due to its CMV promoter (sTRAIL-EGFP plasmid, Figure 3A(i)). 
Specifically, this recombinant TRAIL gene was composed of the soluble form of the human 
Flt3L gene (hFlex) at its 5’ end and the human TRAIL gene at its 3’ end with an isoleucine 
zipper at the N-terminal of TRAIL, which was previously shown to significantly enhance 
the trimerization of the fusion protein as well as its anti-tumor activity [28]. Following 
insertion of the recombinant TRAIL gene into pEGFP-N1, the CMV promoter of the 
resultant sTRAIL-EGFP plasmid was replaced with a HSP70B’ promoter (Figure 3A(ii)) to 
enable strict remote control of gene expression using MCNP-mediated mild magnetic 
hyperthermia, thereby forming the final HSP-sTRAIL plasmid construct. In particular, the 
human HSP70B’ promoter has previously been shown to exhibit highly specific heat 
inducibility with low background activity when compared to other heat shock promoters 
(e.g. HSP70) [40, 41], which can be activated by a number of stresses besides heat (e.g. 
heavy metal-induced oxidative stress) [20]. To confirm the successful construction of the 
plasmid, all steps were evaluated via restriction enzyme analysis (Figure S3) and DNA 
sequencing.
Following plasmid construction, we determined whether the recombinant plasmids could 
produce the TRAIL protein. For this purpose, we performed a simple proof-of-concept study 
by delivering the constitutively active sTRAIL-EGFP plasmid into A2780 ovarian cancer 
cells. About 48 hours after initial transfection, total RNA was collected and reverse 
transcription PCR (RT-PCR) was performed (Figure 3B). From these results, we confirmed 
that TRAIL is produced, whereas it is not present in control samples, which consisted of 
cells that had been transfected with an EGFP plasmid. Lastly, we confirmed that heat could 
be used to specifically induce TRAIL expression in cells transfected with the HSP-sTRAIL 
plasmid. For this purpose, 24 hours after initial transfection, the cells were subjected to mild 
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hyperthermia (41°C) for one hour via exposure to a water bath. Then, 48 hours after initial 
transfection, fluorescence microscopy images of the cells transfected with the heat-inducible 
HSP-sTRAIL plasmid with and without exposure to mild hyperthermia were taken to 
visualize the expression of the TRAIL-EGFP fusion (Figure 3C). These images clearly 
demonstrate that engineered cells only express EGFP when exposed to mild hyperthermia. 
As confirmation, RNA was also collected from samples with and without exposure to mild 
hyperthermia. qPCR analysis of these samples demonstrated that following mild 
hyperthermia at 41°C for one hour, TRAIL expression was significantly increased (3-fold, p 
< 0.05) compared to samples that were not exposed to mild hyperthermia (Figure 3D). 
Altogether, these results confirm that the constructed HSP-sTRAIL plasmid can induce the 
expression of TRAIL in a heat-specific manner.
3.3. Engineering MSCs with the MCNP-PEI/Plasmid Complexes
Following plasmid construction and initial proof-of-concept studies, we sought to optimize 
the MCNP-based transfection into stem cells. For this purpose, we engineered adipose-
derived MSCs (AD-MSCs) with our MCNP-PEI/plasmid complexes as AD-MSCs represent 
an abundant and accessible source of adult stem cells with the ability to differentiate into 
multiple lineages [42]. Before engineering the AD-MSCs, we initially transfected the AD-
MSCs with MCNP-PEI alone to determine the optimal concentration of MCNP-PEI that can 
be delivered while minimizing cytotoxicity. We observed that the delivery of MCNP-PEI 
alone had minimal cytotoxicity even at concentration as high as 100 µg/mL (~85% cell 
viability 48 hours after transfection, Figure S4A). As such, we used 50 µg/mL for future 
steps as this concentration induced almost no cytotoxicity (~95% cell viability) while also 
exhibiting robust heating capabilities. Next, to complex the PEI-coated MCNPs with the 
HSP-sTRAIL plasmid, we mixed the two components together and incubated them at room 
temperature for 20 minutes. Final characterization of these MCNP-PEI/plasmid complexes 
demonstrated that the size of the MCNP-PEI/plasmid complexes, as measured by DLS, 
increased to a final diameter of 197.5 ± 38 nm (PDI = 0.410) and retained a positive zeta 
potential of +17.8 ± 5.11 mV (Figure 2C).
Subsequently, to engineer the AD-MSCs with our MCNP-PEI/plasmid complexes, we 
delivered MCNP-PEI/plasmid complexes wherein 50 µg/mL of MCNP were complexed 
with increasing concentrations of HSP-sTRAIL plasmid to determine the maximal amount 
of plasmid that could be delivered with our MCNPs without significantly affecting AD-
MSC viability. From this optimization process, we determined that a plasmid concentration 
of 200 ng/mL was optimal. Moreover, it was found that this amount of plasmid could be 
completely complexed using 50 µg/mL of MCNP as determined via Picogreen assay, which 
is a dye that binds to free double-stranded DNA (Figure S4B). Using the optimized 
complexing and transfection conditions, the AD-MSCs maintained a cell viability of ~90% 
following the engineering process (Figure S4C). To characterize the affect that engineering 
had on AD-MSC proliferation in more detail, we performed immunocytochemistry for 
Ki-67 (Figure 4A), which is a mitotic marker that is expressed during all phases of the cell 
cycle except during G0. It was observed that approximately 20% of the AD-MSCS 
expressed Ki-67 and that there was no statistically significant difference between the 
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number of Ki-67 expressing engineered AD-MSCs and unengineered AD-MSC controls 
(Figure 4B).
3.4. Characterizing the Engineered AD-MSCs
After engineering the AD-MSCs with MCNP-PEI/plasmid complexes, we next sought to 
determine whether the act of engineering the AD-MSCs negatively affected their ability to 
differentiate and, more importantly, to migrate to cancers in vivo. AD-MSCs are multipotent 
cells that have been shown to readily differentiate along osteogenic, chondrogenic, and 
adipogenic lineages. Therefore, to confirm that the process of engineering did not 
compromise the ability of the AD-MSCs to differentiate, we compared the ability of 
engineered and unengineered control AD-MSCS to differentiate along an osteogenic 
lineage. Briefly, to induce differentiation along this lineage, the engineered or unengineered 
AD-MSCs were exposed to osteogenic differentiation media for three weeks (Figure S5) 
[43]. After this differentiation period, osteogenic differentiation was quantified via Alizarin 
Red S (ARS) staining, which is typically used to evaluate calcium deposited by cells in 
culture, and qPCR. ARS staining revealed calcium-rich deposits in both engineered and 
unengineered osteogenic AD-MSCs (Figure 5A). Quantification suggested that the 
osteogenic differentiation capability was unaffected by the act of engineering as there was 
no statistically significant difference between the quantity of calcium deposited by 
engineered AD-MSCs and unengineered AD-MSC controls (Figure 5B). Further confirming 
these results, we performed qPCR on key osteogenic genes including osteonectin (ON), 
bone alkaline phosphate (BAP), osteocalcin (OCN), and osteopontin (OPN). As expected, 
all four genes were highly expressed when normalized to non-differentiated control AD-
MSCs (Figure 5C) and no significant difference was found between the engineered 
osteogenic AD-MSCs and the unengineered osteogenic AD-MSCs.
Next, we confirmed that the act of engineering the AD-MSCs did not negatively affect their 
ability to migrate to ovarian tumors in vivo (Figure 5D). To this end, we established a 
metastatic model of ovarian cancer wherein two million A2780 ovarian cancer cells were 
injected intraperitoneally (i.p.) into female nude mice (Figure 5D(i)). To confirm that the 
engineered AD-MSCs could co-localize with ovarian tumors, the mice, which had 
disseminated peritoneal A2780 tumors, were injected with half a million engineered AD-
MSCs or unengineered AD-MSC controls i.p. at 7 days post-tumor implantation (Figure 
5D(ii)). Mice were then harvested after an additional 7 days (Figure 5D(iii)). Multimodality 
imaging was used to identify the various components; luciferase was used to identify the 
A2780 ovarian cancer cells (Figure 5E) and a lipophilic DiD dye was used to label the 
engineered and unengineered AD-MSCs. From Figures 5F and 5G, it can be observed that, 
after the tumors were collected (week 3), the DiD-labeled engineered AD-MSCs (Figure 5F) 
co-localized with the luciferase labeled A2780 cells (Figure 5G) within one week of AD-
MSC injection (Figures S6 and S7). Importantly, it can be seen that there was no significant 
difference between the co-localization of engineered AD-MSCs and unengineered AD-MSC 
controls. As such, these results suggest that the engineered AD-MSCs can act as an effective 
delivery vehicle for gene therapy.
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3.5. Mild Magnetic Hyperthermia-Activated TRAIL Expression from AD-MSCs Can 
Effectively Induce Apoptosis in Ovarian Cancer Cells
TRAIL-expressing MSCs have previously been shown to have the ability to induce cancer 
cell death and decrease tumor and metastasis development in vivo [14]. In these 
experiments, the TRAIL expression was either constitutively active or conditionally 
activated with the addition of doxycycline. However, while TRAIL is largely biocompatible 
with normal cells, as mentioned previously, there have been reports demonstrating potential 
hepatotoxicity in preclinical models when treated with recombinant TRAIL [18, 19].
Addressing this major limitation, we engineered AD-MSCs with MCNP-PEI/plasmid 
complexes, where the plasmid was the heat-inducible HSP-sTRAIL, in order to gain 
spatiotemporal control over therapeutic gene expression. Having already determined that 
mild hyperthermia (induced using a water bath) could be used to activate this plasmid, we 
next sought to induce TRAIL expression from the engineered AD-MSCs using mild 
magnetic hyperthermia, which can be induced remotely and non-invasively by exposing the 
engineered AD-MSCs to an AMF. To this end, we employed the experimental design 
illustrated in Figure 6A. In particular, 24 hours after transfection of the AD-MSCs with 
MCNP-PEI/plasmid complexes, we exposed the cells to an AMF (same conditions as 
described previously) to maintain a temperature of approximately 41°C for one hour 
(Figures 6B and S2B). About 72 hours after initial transfection, we collected the conditioned 
media from the engineered AD-MSCs, which contains TRAIL that was secreted from the 
engineered AD-MSCs, and added it (60:40 ratio with normal A2780 growth media) to the 
A2780 ovarian cancer cells. Following an additional incubation of 48 hours, its therapeutic 
efficacy was evaluated. Importantly, our first observation was that mild magnetic 
hyperthermia alone did not significantly affect AD-MSC viability, which agrees with 
previously published results on the effects of heat on stem cell viability (Figure 6C) [44]. In 
terms of its therapeutic efficacy, A2780 ovarian cancer cells treated with conditioned media 
from the engineered AD-MSCs that were exposed to mild magnetic hyperthermia showed a 
remarkable decrease in cell viability (40% decrease) when compared to those treated with 
conditioned media from engineered AD-MSCs controls that had not been exposed to mild 
magnetic hyperthermia (Figure 6D).
To confirm that this loss in viability was a function of the mild magnetic hyperthermia-
activated secretion of TRAIL from the engineered AD-MSCs, the underlying mechanism 
was explored. It is well-established that TRAIL primarily induces apoptosis by binding to 
death receptor 4 (DR4) and death receptor 5 (DR5), which we confirmed to be expressed in 
A2780 ovarian cancer cells via qPCR (Figure S8A) [45]. As such, we first investigated the 
contribution of the death receptors to the observed decrease in cell viability by treating the 
A2780 cells with monoclonal antibodies blocking DR4 and/or DR5 selectively prior to 
exposure to conditioned media from the engineered AD-MSCs that were exposed to mild 
magnetic hyperthermia. We found that blocking DR4 alone (82.7% cell viability), DR5 
alone (75.7% cell viability), and both DR4 and DR5 (87.7% cell viability) were able to 
abrogate the effect of the conditioned media (Figure S8B). This agrees with our qPCR 
(Figure S8A) and previous results from the literature [46, 47], which show/state that DR4 is 
expressed at higher levels than DR5. Moreover, upon immunodepletion of TRAIL from 
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conditioned media of engineered AD-MSCs that were exposed to mild magnetic 
hyperthermia using magnetic nanoparticles functionalized with anti-TRAIL antibody, it was 
observed that the apoptotic effect of the AD-MSC conditioned media was reversed (90.1% 
cell viability). Next, as it has been reported that TRAIL acts primarily through the activation 
of caspase-8 and subsequent activation of caspase-3 [48], we confirmed that A2780 ovarian 
cancer cells that have been exposed to conditioned media from the engineered AD-MSCs 
that were exposed to mild magnetic hyperthermia exhibited significant activation of 
caspases when compared to those treated with conditioned media from engineered AD-
MSCs controls that had not been exposed to mild magnetic hyperthermia (Figure 6E). 
Lastly, we demonstrated that specific inhibition of caspase-8 (85.2% cell viability) and non-
specific inhibition of caspases (97.9% cell viability) were able to neutralize the effect of the 
conditioned media (Figure S8C). As such, these results confirm that the observed decrease 
in A2780 cell viability is due to the mild magnetic hyperthermia-activated secretion of 
TRAIL from the engineered AD-MSCs.
Finally, we have also conducted in vivo studies, wherein engineered AD-MSCs were 
delivered into a metastatic ovarian cancer mouse model via i.p. injection. Our results suggest 
that engineered AD-MSCs, which secrete TRAIL, are efficacious and can significantly 
decrease tumor volume when compared to unengineered AD-MSC controls as well as 
treatment with a single dose of recombinant TRAIL (5 mg/kg via i.p. injection) over a two-
week period (Figures 6F and S9). Specifically, we found that even after a single dose of half 
a million engineered AD-MSCS (sTRAIL-EGFP plasmid), the overall tumor volume, as 
measured by luminescence intensity, decreased by over 50% (Figure 6G). On the other 
hand, treatment with a single dose of recombinant TRAIL (5 mg/kg) did not decrease tumor 
size. Instead, the size of the tumor in mice that were treated with a single dose of 
recombinant TRAIL remained nearly constant over the two-week period. This agrees with 
previous reports from the literature as recombinant TRAIL is limited by its short half-life. 
As such, treatment with recombinant TRAIL typically requires high doses (1 – 10 mg/kg) 
that are injected daily [49].
4. CONCLUSIONS
In this work, a stimuli-responsive stem cell-based gene therapy was developed to enhance 
the treatment of ovarian cancer. In particular, MCNPs were used for the dual purpose of 
delivering a heat-inducible plasmid encoding TRAIL and remotely activating TRAIL 
secretion in the engineered AD-MSCs via mild magnetic hyperthermia. As such, by 
combining the tumor tropism of the AD-MSCs with the spatiotemporal MCNP-based 
delivery and activation of TRAIL expression, this platform provides an attractive means 
with which to enhance our control over the activation of stem cell-based gene therapies. 
Importantly, we demonstrated that the process of engineering the AD-MSCs did not 
significantly affect their innate proliferation, differentiation, and tumor homing capabilities. 
Moreover, mild magnetic hyperthermia resulted in the selective expression of TRAIL in the 
engineered MSCs, thereby inducing significant ovarian cancer cell apoptosis and death in 
vitro and in vivo.
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Previous studies have demonstrated that mild hyperthermia can be used to activate genes 
[50–53]. However, these reports have primarily focused on simple proof-of-concept studies 
wherein reporter genes were activated in cancer cells. For instance, Ortner et al. used iron 
oxide nanoparticles to deliver a heatinducible luciferase or GFP plasmid to Human 
embryonic kidney 293 (HEK293) cells [51]. In particular, they demonstrated that they could 
regulate reporter gene expression in vitro using magnetic hyperthermia. On the other hand, 
Yamaguchi et al. demonstrated a heat-inducible system for cancer treatment, wherein 
magnetic nanoparticles were used to deliver a heat-inducible plasmid encoding tumor 
necrosis factor alpha (TNF-α) [50]. In this case, these magnetic nanoparticle-plasmid 
complexes were delivered directly to the human lung adenocarcinoma cells (A549) in order 
to induce apoptosis of the lung adenocarcinoma cells. Using this system, the authors were 
able to control the expression of TNF-α in the transfected cancer cells both in vitro and in 
vivo using magnetic hyperthermia, thereby demonstrating a local and effective cancer 
therapy.
While promising, these previous demonstrations are still plagued by the difficulty of actually 
delivering the magnetic nanoparticles and plasmids to the tumor in vivo. As such, they 
would be unable to target cancers in distinct parts of the body where the cancer has 
metastasized and, as a result, would be extremely difficult to translate to the clinic. 
Moreover, the cell lines used in these previous studies are relatively easy to transfect. 
Addressing these challenges, we have demonstrated an advanced heat-activated gene 
therapies in this report, wherein we engineered stem cells in order to take advantage of their 
innate tumor targeting ability. In particular, we are the first to report the use of mild 
magnetic hyperthermia to remotely activate a heat-inducible gene in stem cells. In the future, 
we envision that the biocompatible mSi shell of the MCNP can be filled with chemotherapy 
in order to enhance the effect of TRAIL. For instance, while the delivery of TRAIL has 
already been shown to be effective against cancer cells that have acquired resistance to 
conventional chemotherapy via p53 inactivation, tumor cells have also developed various 
mechanisms to escape TRAIL-induced apoptosis [1]. To this end, a number of studies have 
identified novel combinations that could be used with TRAIL to potentiate its therapeutic 
efficacy. For instance, Kelly et al. has demonstrated that the pretreatment of prostate cancer 
cells with doxorubicin can increase their sensitivity to TRAIL [54].
In conclusion, we have successfully combined synthetic biology with nanotechnology, 
wherein mild magnetic hyperthermia was used to specifically activate genes in stem cells. 
Owing to the great potential of stem cells, the implications of this study go well beyond 
cancer applications, and can potentially be used for a host of applications that range from the 
stimuli-guided differentiation of stem cells for the treatment of injuries such as spinal cord 
or traumatic brain injury to other diseases such as those involving inflammation, wherein 
stem cells can be engineered to conditionally secrete anti-inflammatory molecules. As such, 
we have demonstrated a stimuli-responsive stem cell-based gene therapy using 
multifunctional MCNPs, which could have great potential for both cancer and other 
regenerative applications.
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Mild Magnetic Hyperthermia-Activated Stem Cell-Based Gene Therapy. A) MCNPs 
composed of a ZnFe2O4 magnetic nanoparticle (MNP) core and a mesoporous silica (mSi) 
shell (i) are functionalized with polyethyleneimine (PEI) to allow for complexing with a 
heat-inducible therapeutic plasmid (iii). The MCNPs enhance delivery of the heat-inducible 
plasmid into the adipose-derived mesenchymal stem cells (AD-MSCs) via magnetically-
facilitated uptake (iv–v). These engineered ADMSCs can then be injected in vivo (vi), where 
they innately home to the tumors/metastases. Finally, mild magnetic hyperthermia, via 
exposure of the MCNPs to an alternating magnetic field (AMF), can be used to specifically 
activate the heat-inducible secretion of therapeutic TRAIL from the AD-MSCs (vii). B) The 
heat-inducible plasmid is composed of a HSP70B’ promoter and a secreted form of TRAIL 
(sTRAIL) that is fused to an EGFP reporter.
Yin et al. Page 20














Characterization of the MCNPs. A) HR-TEM image of the MCNPs. B) Higher 
magnification HR-TEM image of the MCNPs shows that the pores are about 3 nm in size. 
C) Size was determined using TEM and dynamic light scattering (DLS). Moreover, the Zeta 
potential was confirmed. The values in the chart are given as mean ± standard deviation. D) 
The MCNPs (25 µg/mL) can be heated to temperatures as high as 47°C after exposure to an 
alternating magnetic field (5 kA/m, 225 kHz) for one hour.
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Characterization of the Heat-Inducible Plasmid. A) Schematic depicting the sTRAIL-EGFP 
plasmid (i), which expresses a sTRAIL-EGFP fusion that is constitutively activate, and the 
HSP-sTRAIL plasmid (ii), which expresses the same sTRAIL-EGFP fusion under the 
control of a heat-inducible HSP70B’ promoter. B) RT-PCR demonstrating the successful 
synthesis of the sTRAIL-EGFP plasmid, which was transfected into A2780 ovarian cancer 
cells. C) Proof-of-concept demonstrating that the HSP-sTRAIL plasmid can be specifically 
activated by heat (1 hour at 41°C in a water bath) as seen via fluorescence imaging due to 
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fusion of TRAIL with EGFP. Scale bar = 50 µm. D) Confirmation of heat-specific TRAIL 
activation was obtained using qPCR (*p < 0.05) and was normalized to transfected cells that 
were incubated at 37°C. GAPDH was used as the housekeeping gene.
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Proliferation of AD-MSCs Engineered with MCNP-PEI/Plasmid Complexes. A) The 
proliferation of unengineered (control) and engineered (MCNP-PEI/plasmid) AD-MSCs was 
evaluated using Ki-67 (red). The nuclei were stained with Hoechst (blue). Scale bar = 50 
µm. B) Approximately 20% of the AD-MSCS expressed Ki-67 and there was no statistically 
significant difference between the two groups (p > 0.05).
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Differentiation and Migration of AD-MSCs Engineered with MCNP-PEI/plasmid 
Complexes. A) To evaluate osteogenic differentiation, engineered or unengineered AD-
MSCs were differentiated for three weeks. Osteogenesis was then quantified via Alizarin 
Red staining. B) Quantification of staining suggested that there was no statistically 
significant difference between the two groups (p > 0.05). C) qPCR of key osteogenic genes 
demonstrated that all four genes were highly expressed over non-differentiated control and 
that no significant difference was found between the engineered and unengineered AD-
MSCs (p > 0.05). GAPDH was used as the housekeeping gene. D) Timeline of the studies 
used to evaluate the tumor homing ability of the engineered and unengineered AD-MSCs. 
E) Luciferase was used to identify the A2780 cells. Luminescence imaging shows the 
establishment of disseminated A2780 tumors. The luminescence intensity goes from blue to 
red, wherein blue is the weakest and red is the strongest. F) One week after the injection of 
AD-MSCs, tumors were collected. Fluorescence imaging shows the DiD-labeled engineered 
and unengineered AD-MSCs. The fluorescence intensity goes from dark red to yellow, 
wherein dark red is the weakest and yellow is the strongest. G) Luminescence imaging of 
the conglomerated tumors demonstrates that the AD-MSCs are able to colocalize with the 
tumors.
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Engineered AD-MSCs Can Effectively Induce Apoptosis When Exposed to Heat. A) 
Timeline of the in vitro study. B) Mild magnetic hyperthermia with an average temperature 
of 41.5°C was maintained for one hour by periodically exposing the engineered AD-MSCs 
to an AMF (5 minutes on, 5 minutes off). C) Mild magnetic hyperthermia alone did not 
significantly affect AD-MSC viability. Moreover, the process of engineering the AD-MSCs 
with MCNP-PEI/plasmid complexes did not significantly affect cell viability. D) To test 
therapeutic efficacy, A2780 ovarian cancer cells were treated with conditioned media from 
the engineered AD-MSCs that were exposed to mild magnetic hyperthermia. A2780 cells 
showed a remarkable decrease in cell viability when compared to those treated with 
conditioned media from engineered AD-MSCs that had not been exposed to mild magnetic. 
E) To confirm the mechanism of action, qPCR for caspases, which are downstream of 
TRAIL, was performed. F) To evaluate in vivo efficacy, we injected half a million AD-
MSCS engineered with MCNP-PEI/plasmid complex, wherein the plasmid was sTRAIL-
EGFP. Unengineered AD-MSCs and a single dose of recombinant TRAIL (5 mg/kg) were 
injected as controls. Tumor volume was followed over two weeks, we found that the size of 
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the tumors decreased significantly (max value at day 0 was 6 × 104 whereas the max value 
on day 14 was 8 × 103) when treated with the engineered AD-MSCs. G) Quantification of 
luminescence intensity shows that the engineered AD-MSCs are significantly better than 
treatment with a single dose of recombinant TRAIL.
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